KemPharm has reported positive results from a Phase I clinical trial of its opioid-based drug candidate, KP201.

The single dose, three-treatment, three-period, six-sequence and cross-over Phase I study included 24 healthy volunteers and showed the drug candidate reduced pain and improved pharmacokinetic profile.

The study also evaluated the serum concentrations of hydrocodone and intact KP201, as well as its safety and tolerability.

KemPharm Research vice-president Sven Guenther said: “The pharmacokinetic profile of KP201 indicates that the prodrug releases hydrocodone…and can deliver additional patient benefits, including reduced potential for abuse as well as reduction or elimination of opioid-induced constipation.”